Table 1. Summary of mutations and SNVs in CRBN and DDB1 in MM cell lines and patients.

IMiD-sensitive MM cell lines	CRBN nucleotide position and change	CRBN amino-acid position and change	DDB1 nucleotide position and change	DDB1 amino-acid position and change
H929 parental, U266, EJM, SKMM2	None		None
OPM-2	G1209A silent heterozygous	T403T	None
KMS-12-BM parental	T735C silent homozygous	Y245Y	None
Intrinsic IMiD-resistant MM cell lines
LP1	None		None
RPMI 8226	None		None
JJN3	None		None
Paired sensitive and acquired resistant cell lines
H929 sensitive control	None		None
H929 4 resistant clones	None		None
KMS-12-BM sensitive control	T735C silent homozygous	Y245Y	None
KMS-12-BM LEN-resistant	T735C silent homozygous	Y245Y	None
KMS-12-BM POM-resistant	T735C silent homozygous	Y245Y	None
MM1S sensitive	None		None
MM1S/R10R LEN-resistant	None		None
ANBL-6 sensitive	None		A909T heterozygous	E303D
	None		C153T silent heterozygous	P51P (rs2230356)
ANBL-6 LEN-resistant	G745T heterozygous	D249Y	A909T heterozygous	E303D
	None		C153T silent heterozygous	P51P (rs2230356)
Patient samples (90)
Newly diagnosed (24)	T735C silent homozygous, C219T silent heterozygous	2 × Y245Y (rs17027638), 1 × H73H	C153T silent heterozygous, C939T silent heterozygous	2 × P51P (rs2230356), 1 × C313C (rs150106100)
RRMM (30)	T735C silent homozygous	2 × Y245Y (rs17027638)	C153T silent heterozygous	4 × P51P (rs2230356)
LEN-resistant RRMM (36)	None		None

Abbreviations: CRBN, cereblon; DDB1, DNA damage-binding protein 1; IMiD, immunomodulatory drug; LEN, lenalidomide; MM, multiple myeloma; POM, pomalidomide; RRMM, relapsed/refractory multiple myeloma; SNV, single-nucleotide variation.